Core Viewpoint - Alpha Cognition Inc. is set to report its fourth quarter and full year 2025 financial results on March 26, 2026, and will provide a business update during a conference call [1]. Financial Results Announcement - The company will issue a press release detailing its financial results and business highlights on March 26, 2026, after market close [1]. - A conference call will follow the release to review financial and operating results, scheduled for 4:30 PM ET [1]. Product Development and Clinical Studies - Alpha Cognition is focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury (mTBI) [1]. - The company’s drug ZUNVEYL® is a new generation acetylcholinesterase inhibitor with minimal gastrointestinal side effects, targeting neuronal nicotinic receptors [1]. - Alpha Cognition is also developing ALPHA-1062 in combination with memantine for moderate to severe Alzheimer's dementia and as an intranasal formulation for cognitive impairment with mTBI [1]. Upcoming Presentations and Studies - The company will present new clinical data on ZUNVEYL at the American Association of Geriatric Psychiatrists conference in April 2026 and the Neuroscience Education Institute Spring Congress in May 2026 [2]. - Alpha Cognition announced the enrollment of the first patient in the BEACON Phase 4 real-world effectiveness study to assess ZUNVEYL's impact in long-term care settings [2]. Patent Developments - The United States Patent and Trademark Office has issued a new patent covering dosing regimens for ZUNVEYL, enhancing the company's intellectual property portfolio [2].
Alpha Cognition (Nasdaq: ACOG) to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, March 26, 2026